Based on 1 active firms as of Nov 18, 2026 (365-day activity window).
12-MONTH PRICE TARGET
—
Average target across 0 active firms as of Nov 18, 2026 vs $0.14 current
Highest Target—
Average Target—
Lowest Target—
AIM analyst recommendation trends
86420
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Strong BuyBuyNeutralSellStrong Sell
RATING
JUN
JUL
AUG
SEP
OCT
NOV
Strong Buy
0
0
0
0
0
0
Buy
1
1
1
1
1
1
Neutral
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
1
1
1
1
1
1
As of Nov 18, 2026, 1 of 1 active firms rate AIM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AIM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.10 – $-0.10 · 1 analysts · -86% YoY
Next period, 1 analysts expect AIM ImmunoTech Inc to earn $-0.10 a share (range $-0.10 – $-0.10), versus $-0.69 a year earlier. Full-year consensus is $-0.78, growing to $-0.37 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $74.0K, rising to $50.0K next year.
Top analysts covering AIM ImmunoTech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AIM.
#1
Jason McCarthy
Maxim Group · Rank #567
Buy
$1.50+990.1% to target
Overall win rate
30%
+ Follow
AIM stock forecast FAQ
Is AIM stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 18, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover AIM?+
1 active firms have a recognized rating on AIM ImmunoTech Inc as of Nov 18, 2026.
Who is the most accurate analyst covering AIM?+
Among analysts who currently cover AIM, Jason McCarthy of Maxim Group has the strongest overall Quantellect track record (Rank #567). Their current call is Buy with a $1.50 target.
What is AIM ImmunoTech Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.10 – $-0.10) across 1 analysts. Full-year EPS is projected at $-0.78, rising to $-0.37 the following year.
How much revenue is AIM ImmunoTech Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $74.0K, growing to $50.0K next year.
Have analysts been upgrading or downgrading AIM lately?+
As of Nov 18, 2026, 1 of 1 active firms rate AIM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AIM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.